| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.DRUGALCDEP.2008.01.025 |
| P8608 | Fatcat ID | release_76ef5zwwyjfjffq5iy3kcjx7fu |
| P698 | PubMed publication ID | 18355989 |
| P5875 | ResearchGate publication ID | 5496462 |
| P50 | author | Markus Heilig | Q42632514 |
| P2093 | author name string | Johan Kakko | |
| Ihsan Sarman | |||
| P433 | issue | 1-2 | |
| P921 | main subject | opiate dependence | Q18555117 |
| P304 | page(s) | 69-78 | |
| P577 | publication date | 2008-03-19 | |
| P1433 | published in | Drug and Alcohol Dependence | Q5308875 |
| P1476 | title | Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series | |
| P478 | volume | 96 |
| Q34457456 | (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy |
| Q36702592 | A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes |
| Q37261863 | A Swedish Population-based Study of Adverse Birth Outcomes among Pregnant Women Treated with Buprenorphine or Methadone: Preliminary Findings |
| Q35190477 | A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium |
| Q47573956 | A retrospective cohort study of the health of children prenatally exposed to methadone, buprenorphine or naltrexone compared with non-exposed control children. |
| Q35621921 | Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates? |
| Q34277168 | BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. |
| Q38127854 | Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy |
| Q44340523 | Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. |
| Q28073116 | Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child |
| Q44333430 | Buprenorphine exposure in infants of opioid-dependent mothers at birth |
| Q47162080 | Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder in Pregnancy: Relationship to Neonatal Opioid Withdrawal Syndrome. |
| Q37871042 | Buprenorphine for the treatment of perinatal opioid dependence: pharmacology and implications for antepartum, intrapartum, and postpartum care |
| Q42566902 | Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. |
| Q35863900 | Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review |
| Q38115201 | Buprenorphine use in pregnant opioid users: a critical review |
| Q44350533 | Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study |
| Q37801439 | Buprenorphine‐Based Regimens and Methadone for the Medical Management of Opioid Dependence: Selecting the Appropriate Drug for Treatment |
| Q33787848 | Chronic in utero buprenorphine exposure causes prolonged respiratory effects in the guinea pig neonate |
| Q34076552 | Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women |
| Q37467788 | Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes |
| Q37191073 | Confounding of the Comparative Safety of Prenatal Opioid Agonist Therapy |
| Q35075284 | Depression-like effect of prenatal buprenorphine exposure in rats |
| Q93165361 | Differences in hospital length of stay between neonates exposed to buprenorphine versus methadone in utero: A retrospective chart review |
| Q34186492 | Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates |
| Q35738851 | Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: Implications for pregnant women |
| Q57169315 | Early life stress and environmental influences on the neurodevelopment of children with prenatal opioid exposure |
| Q34721038 | Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication |
| Q92288216 | Effects of opioids on the parental brain in health and disease |
| Q37632852 | Evaluation and management of opioid dependence in pregnancy |
| Q40777859 | Factors associated with buprenorphine versus methadone use in pregnancy |
| Q34581552 | Fetal neurobehavioral effects of exposure to methadone or buprenorphine |
| Q33807411 | Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine |
| Q33862878 | Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women |
| Q35201603 | Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine |
| Q44336832 | Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women |
| Q34078458 | Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy |
| Q47766427 | Maternal and neonatal outcomes following methadone substitution during pregnancy |
| Q35220378 | Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study |
| Q38679144 | Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women. |
| Q35196693 | Monitoring pregnant women's illicit opiate and cocaine use with sweat testing |
| Q37999447 | Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research |
| Q30499416 | Neonatal abstinence syndrome after methadone or buprenorphine exposure |
| Q44072255 | Neurobehavioural development of preschool-age children born to addicted mothers given opiate maintenance treatment with buprenorphine during pregnancy |
| Q30249760 | Opioid Use Disorder in Pregnancy: Health Policy and Practice in the Midst of an Epidemic. |
| Q33688813 | Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options |
| Q24628765 | Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome |
| Q35837987 | Opioid dependent and pregnant: what are the best options for mothers and neonates? |
| Q36810933 | Pharmacotherapy and pregnancy: highlights from the Second International Conference for Individualized Pharmacotherapy in Pregnancy. |
| Q38889054 | Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital: a 30-year retrospective study |
| Q38242505 | Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis |
| Q36698128 | Prescription Opioids in Pregnancy and Birth Outcomes: A Review of the Literature |
| Q35023911 | Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison |
| Q34199044 | Review of the assessment and management of neonatal abstinence syndrome |
| Q33870389 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence |
| Q40386069 | The comparative safety of buprenorphine versus methadone in pregnancy-what about confounding? |
| Q30239085 | The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care |
| Q37310917 | The opioid-exposed newborn: assessment and pharmacologic management |
| Q40423803 | The relationship between gestational age and the severity of neonatal abstinence syndrome. |
| Q42608613 | Transfer of buprenorphine into breast milk and calculation of infant drug dose |
| Q33760424 | Treating Women Who Are Pregnant and Parenting for Opioid Use Disorder and the Concurrent Care of Their Infants and Children: Literature Review to Support National Guidance |
| Q39436476 | Treating opioid use disorders during pregnancy: historical, current, and future directions |
| Q92897924 | Update on the Treatment of Opioid Use Disorders in Pregnancy |
| Q26829140 | Update on the clinical use of buprenorphine: in opioid-related disorders |
| Q45847009 | Mise à jour sur l’utilisation clinique de la buprénorphine: pour les troubles reliés aux opioïdes |
Search more.